Held by 3 specialist biotech funds
High Convergence# Signal Note: Perceptive Advisors Initiates AQST Position Edelman's $4.8M entry into Aquestive suggests conviction in the company's PharmFilm platform economics or near-term catalysts, likely centered on AQST-002 (seizure disorder) or commercial traction in marketed products (Naurex, Ontivos).
AI analyst context — unlock full analysis
# Signal Note: EcoR1 Capital Initiates $17M Position in AQST EcoR1's entry into Aquestive suggests conviction in the company's specialty pharma portfolio, likely driven by near-term catalysts in its core franchises (migraine via Ubrelvy and Nurtec ODT, and epilepsy via Fintepla). The $17M position size indicates moderate conviction rather than transformational belief, consistent with EcoR1's growth-stage crossover strategy. Key near-term monitoring points: Nurtec ODT market share gains in the competitive CGRP antagonist space and Fintepla adoption trajectory in rare seizure disorders.
+ 1more — see how much conviction went in
See the Full Story